Endospan Announces Positive One-Year Data from TRIOMPHE FDA Pivotal Study For the NEXUS® Aortic Arch Stent-Graft System

2026-02-03 - 14:15

TEL AVIV, Israel -- Endospan, a privately held company pioneering solutions for the endovascular repair of aortic arch disease, today announced the one-year results of their TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® Aortic Arch Stent-Graft System presented during the Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans. Read More